How have the shares performed?
Sigilon Therapeutics Inc. (SGTX) saw downtrend of -8.04% in the recent trading with $10.29 being its most recent. The current price level -81.06% lower than the highest price of $54.32 marked by the stock while trading over the past 52-weeks, whereas it is 5.00% higher than the lowest price of $9.80 the company dropped to over past 52-weeks. The latest news story on SGTX appeared in GlobeNewswire under the title “Sigilon Therapeutics Appoints Philip Ashton-Rickardt, Ph.D., as Chief Scientific Officer” on Jun-14-21.
Squeezing the time span to 30 day period shows us the stock is currently trading -27.28% below one month high and is +5.00% above of the lowest during that time. Looking into the simple moving average, Sigilon Therapeutics Inc. (SGTX)’s stock stands at a SMA-50 of $13.94 while that of 5-day is reading $10.76.
Do analysts rate it as a buy, sell or hold?
Irrespective of recent performance, what’s important is what the future holds. In uncertain economic times, a clear picture is difficult to get. Analysts generally have a good understanding of the market works, which gives them a leg up in making predictions. Currently, the stock has been recommended as Strong Buy by 4 of the brokerage firms. Analyst ratings are often compiled into a single score from 1 to 5. The score of 1 signifies buy or strong buy, the score of 2 signifies outperform, the score of 3 means hold, and the score of 4 indicates underperform. The simple numeric range of brokerage firm referenced at the scale of 1 to 5 reads a current average recommendation of 1.70 for the stock.
Sigilon Therapeutics Inc. Earnings – What Happened With SGTX
Coming around sales and income figures, publically trading companies under normal circumstances post earnings and revenues near to average estimates by the Wall Street analysts, but those could came either above or below estimates and known as surprise factor. Sigilon Therapeutics Inc. (SGTX) last released financial results for the quarter that ended 3/30/2021, posting a surprise factor of -1.70% for net revenue. During the reported three-month period, company’s sales were $2.96 billion while analysts on average were estimating the same to be $3.1 million.
SGTX – Sigilon Therapeutics Inc. Stock Earnings Estimates
The perspective of Sigilon Therapeutics Inc. (NASDAQ:SGTX)’s current quarter earnings identifies that analysts are in consensus over the estimate of -0.59 for stock’s EPS in the current quarter. 4 analysts covering the stock at Wall Street were agreed upon that EPS consensus. Company’s EPS for the last quarter was -0.6.
Investors get the exact data about the key information of institutional ownership in a listed company through its 13F filings at the Stock Exchange Commission (SEC). The total number of common shares currently owned by the public is 28.79 million. SGTX does have institutional investors; and they hold 62.30% of the stock.
Sigilon Therapeutics Inc. – Insider Activity and Holdings
Moreover, the latest SEC filings also revealed that stock came across 0 new insider purchases involving 0 shares. On the other hand, SGTX declared 200,000 shares have been sold in 1 insider transactions over the past three months.
As on Mar 30, 2021, Flagship Pioneering Inc. was the top most holder in Sigilon Therapeutics Inc. (NASDAQ:SGTX) with an ownership of 10.37 million shares of the company or 32.89% of the stake worth $231.78 million. The filing also reveals Canada Pension Plan Investment Board as the second largest holder in the company with a control over 4.71% of the outstanding shares. Its stake is worth $33.19 million for having 1.49 million shares in hand.
Blackrock Inc. also came holding a key position in the company during the recent quarter and it now holds 4.08% of the outstanding shares. With this there are now 73 institutions which have possession in SGTX’s shares.
Currently, the stock has been recommended as Strong Buy by 4 of the brokerage firms. Analyst ratings are often compiled into a single score from 1 to 5. The score of 1 signifies buy or strong buy, the score of 2 signifies outperform, the score of 3 means hold, and the score of 4 indicates underperform. The simple numeric range of brokerage firm referenced at the scale of 1 to 5 reads a current average recommendation of 1.70 for the stock.
The liquidity is a key characteristic of any stock and is the main point of focus of both short-term as well as long term investors before start trading into a stock. In recently reported quarter, current ratio recorded by Sigilon Therapeutics Inc. was 4.34 while posting a debt to equity ratio of 0.00. The count was 21.69 for long-term debt to equity ratio.